Top Industry Leaders in the Asia Pacific Glaucoma Treatment Market
Santen Pharmaceutical Co., Ltd. announces regulatory approval for its Rhokinase inhibitor, Roclatan®, in mainland China, expanding its reach in the largest Glaucoma market in the Asia-Pacific region.
Senju Pharmaceutical Co., Ltd. receives marketing authorization for its prostaglandin analog Travatan® in Indonesia, offering another treatment option for patients in the region.Aeon Vis launches its glaucoma drainage implant, Aquaflow®, in South Korea, providing a minimally invasive alternative for managing severe glaucoma cases.
Glaukos Corporation partners with Alcon Laboratories to distribute its iStent® Inject Trabecular Micro-Bypass System in India and South Korea, leveraging Alcon's established distribution network to reach more patients.
Merck & Co., Inc. collaborates with Bausch + Lomb to develop and commercialize novel therapies for glaucoma in the Asia-Pacific region, combining their expertise and resources to accelerate drug development and market access.
List of Asia-Pacific Glaucoma Treatment Key Companies in the Market
- Novartis AG
- Pfizer Inc.
- Allergan
- Merck & Co.
- Ocular Therapeutix Inc
- pSivida Corp
- Icon Bioscience Inc
- Amorphex Therapeutics LLC.
- Ellex
- Quantel
- Lumenis
- and Lightmed
